Thus, piR-52207 and piR-33733 promote ovarian cancer oncogenes via involvement in multiple cell-signaling pathways at the post-transcriptional level, supporting them as possible therapeutic targets for ovarian cancer [73]. This evidence concerns the gene PIR and ovarian carcinoma.